Idioma:

Anti-Angiogenic Therapy: Current Challenges and Future Perspectives

Lopes-Coelho, Filipa ; Martins, Filipa ; Pereira, Sofia A ; Serpa, Jacinta

International journal of molecular sciences, 2021-04, Vol.22 (7), p.3765 [Periódico revisado por pares]

Switzerland: MDPI AG

Texto completo disponível

Citações Citado por

Enviar para

Título:
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Autor: Lopes-Coelho, Filipa ; Martins, Filipa ; Pereira, Sofia A ; Serpa, Jacinta
Assuntos: Angiogenesis ; Angiogenesis Inhibitors - therapeutic use ; Animals ; anti-angiogenic therapy ; Antiangiogenic agents ; Antiangiogenics ; Blood vessels ; Cancer ; Cancer therapies ; cancer therapy ; Colorectal cancer ; drug resistance ; Drugs ; Fibroblasts ; Growth factors ; Humans ; Immunosuppressive agents ; Liver cancer ; Medical prognosis ; Metastasis ; Molecular modelling ; neo-angiogenesis ; Neoplasm Proteins - metabolism ; Neoplasms - blood supply ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Neoplasms - pathology ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Pathologic - metabolism ; Neovascularization, Pathologic - pathology ; new targets ; Rehabilitation ; Review ; Tumor cells ; Tumor microenvironment ; Tumor Microenvironment - drug effects ; Tumors ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - metabolism ; VEGF
É parte de: International journal of molecular sciences, 2021-04, Vol.22 (7), p.3765
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere with mechanisms of angiogenesis related to tumor microenvironment might represent a promising strategy. In this review, we deepened research on the molecular mechanisms underlying anti-angiogenic strategies and their failure and went further into the alternative mechanisms that impact angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies.
Editor: Switzerland: MDPI AG
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Anti-Angiogenic Therapy: Current Challenges and Future Perspectives

Lopes-Coelho, Filipa ; Martins, Filipa ; Pereira, Sofia A ; Serpa, Jacinta

Switzerland: MDPI AG

Buscando em bases de dados remotas. Favor aguardar.